Skip to content
HAYW

Hayward Holdings, Inc.

Hayward Holdings, Inc. Q3 FY2025 earnings call

October 29, 2025 · fiscal period ended 2025-09

EPS · actual vs est

$0.14 / $0.12Beat +15.8%

Revenue · actual vs est

$237.2M / $231.5MBeat +2.5%
Ask about this call

Summary

Generated 2025-10-29

Management highlights

  • Strong third quarter results with net sales up 7% and adjusted EBITDA up 16%. Gross profit margin expanded 150 basis points to 51.2% and adjusted EBITDA margin up 170 basis points to 24.2%. - Reduced net leverage to 1.8x, lowest in nearly 4 years. - Advancing strategic initiatives: expanding customer relationships, developing innovative products (e.g., OmniX automation platform), leveraging operational excellence. - Aggressively executing tariff mitigation actions, reducing direct sourcing from China to 3% of COGS by year-end. - Ramping up sales/marketing in high-value regions, improving customer experience with Hayward Hub centers and AI tools.
View in transcript ↓

Segment performance

North America: Net sales increased 7% to $208 million, with net price realization up 7% and volume stable. Gross profit margin increased 50 basis points to 52.8%. Europe and Rest of World: Net sales increased 11% to $36 million, with a 1% reduction in net price offset by 8% higher volume and favorable foreign currency translation. Gross profit margin increased 750 basis points to 41.9% sequentially from 38.9% in Q2.

View in transcript ↓

Guidance

  • Raised full-year net sales guidance to 4%-5.5% increase (previously 2%-5%), adjusted EBITDA guidance to 5%-7% increase to $292M-$297M (previously $280M-$290M). - Increased free cash flow guidance to approximately $170M.
View in transcript ↓

Risks

  • Uncertain tariff environment. - Potential new tariffs affecting margins. - Geopolitical uncertainty impacting supply chain.
View in transcript ↓

Q&A highlights

Q: Ryan Merkel on demand season progress and early buy reception A: Kevin Holleran discussed seasonal progress, strong September sales, balanced growth across markets, and early buy tracking expectations Q: Saree Boroditsky on new products and price vs volume A: Kevin Holleran talked about investments in new products like OmniX, and Eifion Jones on no major trade-offs seen yet Q: W. Andrew Carter on private label and exposure A: Kevin Holleran discussed private label risks and confidence in innovation and distribution Q: Mike Halloran on capital allocation and M&A A: Eifion Jones and Kevin Holleran talked about CapEx plans, M&A opportunities, and ChlorKing integration Q: Jeffrey Hammond on Q4 comp and aftermarket A: Kevin Holleran and Eifion Jones discussed Q4 comp headwind and aftermarket resilience Q: Brian Lee on international margins and pricing A: Eifion Jones talked about European margin improvement and pricing outlook for 2026 Q: Nigel Coe on tariff refunds and supply chain A: Eifion Jones and Kevin Holleran discussed tariff refunds and progress in reducing China sourcing

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.14$0.12+15.8%
Revenue$237.2M$231.5M+2.5%

Transcript

October 29, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.